• Skip to primary navigation
  • Skip to content
  • Skip to footer
Gynesonics

Gynesonics

Advancing technology. Improving women's lives.

  • Sonata Fibroid Treatment
    • About Uterine Fibroids
    • The Sonata® System
    • Visit SonataTreatment.com
  • In the News
    • Sonata In the News
    • Press Releases
  • Company
    • About Us
    • Management
    • Investors
    • Board of Directors
    • Awards
    • Compliance
    • Careers
  • Resources
    • Safety Information
    • Education Resource Center
    • Request for Medical or Scientific Information
  • Manuals
  • Contact Us

Gynesonics Names Kelly U. Petrucci Vice President of Healthcare Economics and Market Access

November 8, 2019 by michelle

Joins Experienced Team to Accelerate Global Launch of the new Sonata 2 System

Redwood City, CA – November 8, 2019 – Gynesonics, a women’s healthcare company focused on the development of minimally-invasive solutions for symptomatic uterine fibroids, announced today that medical device executive Kelly U. Petrucci has been named Vice President of Healthcare Economics and Market Access. Petrucci reports directly to President and CEO Christopher M. Owens.

“Kelly brings strong leadership and valuable experience to the organization with the ability to develop and drive healthcare policy, coverage, coding and broad market strategies at this critically important time for Gynesonics,” Owens said.  “As we prepare for a major expansion with the upcoming full launch of our new Sonata 2 System, we will draw on her valuable experience to help accelerate our progress with payer coverage and market access by furthering the impressive value proposition that Sonata provides to payers, providers, and healthcare facilities.  Kelly has a proven track record of successfully leading these efforts.  We are excited to have her as part of our team.”

“I am excited to join Gynesonics and its goal of changing healthcare delivery for women who suffer from this debilitating disease of symptomatic fibroids,” Petrucci said.  “I am impressed with the level of clinical evidence developed to commercialize and launch the Sonata System, and the significant and growing body of peer reviewed publications.  My goal is to ensure women have access to quality and cost responsible care.  Currently, 1 in 3 women struggle with fibroids, with hysterectomy still being the leading procedure for treatment.  Sonata provides a new option to address a current gap in treatment for women and is the only technology that can treat up to 80% of fibroid types transcervically, without incisions while preserving the uterus.  This is an important advancement and patients need access.”

Prior to Gynesonics, Ms. Petrucci successfully developed and implemented medical policy strategies for a variety of global medical device and pharmaceutical companies.  She also has significant experience in value-based agreements, creation of health policy, branding, sales and strategic product launch activities.

Previously, Ms. Petrucci was Director of Payer Relations and Value Based Offers with Boston Scientific, where Kelly supported technologies such as Watchman, HeartLogic and Eluvia.  Kelly has supported other large organizations such as AstraZeneca, as a Regional Account Director. Prior to that, she was National Account Director, Health Care Economics & Policy for AngioDynamics; Regional Manager-Managed Markets for Touchpoint Solutions and helped launch a number of generations of CGM with Dexcom.

Ms. Petrucci is a graduate of Siena College with a bachelor’s degree in Business Marketing Management, with a minor in Business Health Care Administration.

About Sonata System

new Sonata® 2 System, the next generation of Gynesonics’ technology platform, uses radiofrequency energy to ablate fibroids under intrauterine sonography guidance. The Sonata 2 System, including the SMART Guide, enables the operator to target fibroids and optimize ablations within them. Sonata System’s design provides a straightforward, transcervical access for a uterus preserving, incision-free fibroid treatment. This intrauterine approach is designed to treat a wide range of fibroid types while avoiding the peritoneal cavity.

For Indication and Safety Information, or to learn more about the Sonata System, visit gynesonics.com/sonatasystem.

About Gynesonics

Gynesonics is a women’s healthcare company focused on advancing women’s health, by developing minimally invasive, transcervical, uterus-preserving, incision-free technologies for diagnostic and therapeutic applications. Gynesonics has developed the new Sonata 2 System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids. The Sonata 2 System is CE marked for distribution in the European Economic Area and FDA cleared for sale in the United States.  Gynesonics is a privately held company with headquarters in Redwood City, CA. For more information, go to www.gynesonics.com

CONTACT: Chris Owens, Gynesonics President and CEO +1.650.216.3860 www.gynesonics.com

Filed Under: Press Releases

Footer

  • Privacy Policy
  • Terms of Use
  • Patents
  • Safety Information

© Copyright 2021 Gynesonics · All Rights Reserved · WS 05198 Rev. H

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

You can adjust all of your cookie settings by navigating the tabs on the left hand side.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Privacy Policy

More information about our Privacy Policy